Navigation Links
CoLucid Pharmaceuticals Appoints Matthew Dallas as Chief Financial Officer and Treasurer
Date:2/9/2015

DURHAM, N.C., Feb. 9, 2015 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced today the appointment of Matthew Dallas as Chief Financial Officer and Treasurer. Simultaneous with the announcement, CoLucid announced the retirement of Tim C. Gupton, CPA. Tim has been the CFO for CoLucid since its inception, and was also a partner in Hughes Pittman & Gupton, LLP.

"We are excited to have Matt join our team as he has extensive financial leadership skills and brings valuable strategic financial and operational  experience to our team, especially as we are initiating our Phase 3 SAMURAI study," said Thomas P. Mathers, Chief Executive Officer of CoLucid.  "We also wish to thank Tim Gupton for his prior leadership and helping CoLucid emerge as a leader in migraine therapy, and wish him well in retirement," he added.

Mr. Dallas has more than 18 years of financial management experience including 16 years in the life sciences industry. Prior to joining CoLucid, Matt was the Vice President of Finance and Treasurer at AVEO Oncology with responsibility for AVEO's Finance, Information Technology, and Facilities functions.  Matt previously worked at Genzyme Corporation, NEN Life Sciences, and Kimberly-Clark Corporation where he held various positions of increasing responsibility in finance and accounting. Mr. Dallas holds a B.S. in Finance from the University of Tennessee in Knoxville.

"I am excited to join the CoLucid team and help initiate our ambitious Phase 3 program for lasmiditan," said Mr. Dallas.

ABOUT LASMIDITAN

Lasmiditan has been designed to deliver efficacy in acute migraine without the vasoconstrictor activity associated with previous generations of migraine therapies.  It selectively targets 5-HT1F receptors expressed in the trigeminal pathway.  Its novel chemical class and differentiated site and mechanism of action led to lasmiditan's designation as a "ditan," a new drug class, by the INN and USAN.

CoLucid has successfully completed seven clinical studies for Lasmiditan, including a Phase 2b study treating a single migraine attack in 391 patients, as well as a TQTc study. Phase 3 development will address major unmet medical needs in patients who are poorly served currently by available therapies to include patients with risk factors for cardiovascular disease who may not be able to take triptans.

We have a Special Protocol agreement with the FDA for SAMURAI which includes two novel endpoints for the approval of acute migraine therapies—a primary endpoint of the proportion of patients who are free of headache pain at 2 hours and a key secondary endpoint of the proportion of patients who no longer suffer from their most bothersome associated symptom of migraine (nausea, photophobia, phonophobia) at 2 hours.

ABOUT MIGRAINE

Migraine is ranked as the seventh highest cause of global disability and in the top 10 causes of disability in 14 of 21 world regions studied, according to findings by the Global Burden of Disease Survey 2010 conducted by the World Health Organization. It is the leading cause of disability among neurological disorders.  An estimated 36 million Americans have migraine, which is more than have asthma or diabetes combined.  Migraine can be extremely disabling and costly, accounting for more than $20 billion in direct (e.g. doctor visits, medications) and indirect (e.g. missed work, lost productivity) expenses each year in the United States.

ABOUT COLUCID PHARMACEUTICALS, INC.

CoLucid was founded by Pappas Ventures and is developing oral Lasmiditan for the acute treatment of migraine headache and intravenous Lasmiditan for treatment of headache pain by health care professionals.

CoLucid is partnered with ILDONG Pharmaceutical Co, Ltd, under a distribution and supply agreement for Lasmiditan, in South Korea and Southeast Asia.

For more information, please visit CoLucid at www.colucid.com.

Logo - http://photos.prnewswire.com/prnh/20130626/LA37332LOGO

 


'/>"/>
SOURCE CoLucid Pharmaceuticals, Inc
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. CoLucid Pharmaceuticals and ILDONG Pharmaceutical Enter into a Distribution and Supply Agreement for Lasmiditan, a Novel Agent for Acute Migraine
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
4. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
5. Access Pharmaceuticals Reports First Quarter Results
6. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
7. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
8. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
9. Aveo Pharmaceuticals, Inc. Sued by Investor
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
11. Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2020)... ... June 24, 2020 , ... ... of common questions on County Line Chiropractic’s YouTube channel. Dr. Vivian ... County Line Chiropractic has six locations in the South Florida area, including the ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... the "Company"), a leading provider of center-based, Applied Behavioral Analysis ("ABA") therapy, ... center-based ABA provider in the greater-Indianapolis market. This acquisition will make Lighthouse ...
(Date:6/19/2020)... Mo. (PRWEB) , ... June 19, 2020 , ... ... end hunger in individuals diagnosed with food allergies and celiac disease announced the first ... Allergy. , This webinar is scheduled for Friday, June 19, 2020, from 11:00, ...
Breaking Medicine Technology:
(Date:6/28/2020)... ... June 26, 2020 , ... Medisend ... provide high-quality, intensive education and training that prepares graduates for professional careers as ... member of the Board of Trustees. , Ms. Williams currently serves as Associate ...
(Date:6/28/2020)... TEMECULA, Calif. (PRWEB) , ... June 26, 2020 ... ... been tougher. Inland Detox, the Inland Empire’s premier residential addiction treatment center, proudly ... of services that now includes special preparation for recovery in a world affected ...
(Date:6/28/2020)... ... June 27, 2020 , ... The secret of surviving a pandemic with one’s ... toilet paper. Yet, it was the first product to disappear off the shelves when ... you have stockpiled, the less need to venture out, the longer you can “survive”. ...
(Date:6/28/2020)... MILWAUKEE (PRWEB) , ... June 28, 2020 , ... ... allergy/immunology societies around the world, dedicates World Allergy Week, from June 28 to ... pandemic caused by SARS CoV-2. , COVID-19, short for “coronavirus disease 2019”, is ...
(Date:6/25/2020)... ... June 25, 2020 , ... Denials Management, Inc. has just published The ... when filing appeals for denials of mental health and substance use disorder (MH/SUD) treatment ... their appeal rights and explain the steps in the appeals process. Complimentary copies ...
Breaking Medicine News(10 mins):